Resum
© 2019, © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
Idioma original | Anglès |
---|---|
Número d’article | e1618178 |
Revista | Molecular and Cellular Oncology |
Volum | 6 |
Número | 5 |
DOIs | |
Estat de la publicació | Publicada - 1 de gen. 2019 |